% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:169319,
      author       = {K. Hemminki$^*$ and A. Försti$^*$ and A. Hemminki and B.
                      Ljungberg and O. Hemminki},
      title        = {{P}rogress in survival in renal cell carcinoma through 50
                      years evaluated in {F}inland and {S}weden.},
      journal      = {PLOS ONE},
      volume       = {16},
      number       = {6},
      issn         = {1932-6203},
      address      = {San Francisco, California, US},
      publisher    = {PLOS},
      reportid     = {DKFZ-2021-01413},
      pages        = {e0253236 -},
      year         = {2021},
      abstract     = {Global survival studies have shown favorable development in
                      renal cell carcinoma (RCC) treatment but few studies have
                      considered extended periods or covered populations for which
                      medical care is essentially free of charge. We analyzed RCC
                      survival in Finland and Sweden over a 50-year period
                      (1967-2016) using data from the NORDCAN database provided by
                      the local cancer registries. While the health care systems
                      are largely similar in the two countries, the economic
                      resources have been stronger in Sweden. In addition to the
                      standard 1- and 5-year relative survival rates, we
                      calculated the difference between these as a measure of how
                      well survival was maintained between years 1 and 5. Relative
                      1- year survival rates increased almost linearly in both
                      countries and reached $90\%$ in Sweden and $80\%$ in
                      Finland. Although 5-year survival also developed favorably
                      the difference between 1- and 5-year survival rates did not
                      improve in Sweden suggesting that the gains in 5-year
                      survival were entirely due to gains in 1-year survival. In
                      Finland there was a gain in survival between years 1 and 5,
                      but the gain in 1-years survival was the main contributor to
                      the favorable 5-year survival. Age group specific analysis
                      showed large survival differences, particularly among women.
                      Towards the end of the follow-up period the differences
                      narrowed but the disadvantage of the old patients remained
                      in 5-year survival. The limitations of the study were lack
                      of information on performed treatment and clinical stage in
                      the NORDCAN database. In conclusion, the available data
                      suggest that earlier diagnosis and surgical treatment of RCC
                      have been the main driver of the favorable change in
                      survival during the past 50 years. The main challenges are
                      to reduce the age-specific survival gaps, particularly among
                      women, and push survival gains past year 1.},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34157049},
      doi          = {10.1371/journal.pone.0253236},
      url          = {https://inrepo02.dkfz.de/record/169319},
}